CC2018: New Key to Cancer Cure: Checkpoint Inhibitor Therapy (C)

This session has been identified and designated as Credit to Meet ACS Accreditation/Verification Requirements for Cancer.

Session Description

This Panel Session will provide an update on recent Food and Drug Administration (FDA) approval of Programmed Death Receptor 1 Ligand (PD L1)-directed immunotherapy in Merkel cell carcinoma, and it will describe the implications of this advance for other solid tumors associated with viral etiologies.

Course Outline

  • Lessons from Checkpoint Inhibitor Treatment of Merkel Cell Carcinoma 
    Howard L. Kaufman, MD, FACS, Boston, MA
  • Advances in Immunotherapy of Anal Cancer
  • Cathy Eng, MD, Houston, TX
  • The Shifting Role of Surgical Management in the Era of Immuno-Oncology
    Ken Tanabe, MD

Target Audience

  • Practicing surgeons
  • Residents

Learning Objectives

  • Apply new knowledge and ideas to improve their surgical practice
  • Adapt concepts and quality measures in support of research advancements
  • Enhance the quality of patient care

Contact

Course summary
Available credit: 
  • 0.00 AMA PRA Category 1 Credit™
  • 0.00 Self Assessment Credit
  • 0.00 Certificate of Completion
Course opens: 
10/05/2018
Course expires: 
12/31/2019


Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website: http://www.accme.org/requirements/accreditation-requirements-cme-providers/policies-and-definitions/financial-relationships-and-conflicts-interest

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity.  Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation. 

(Download the full list of disclosures.)

Faculty and Disclosures

Howard L. Kaufman, MD, FACS, Boston, MA - Replimune, Inc.: Compensation: CMO
Robert L. Ferris, MD, Pittsburgh, PA -Amgen: Advisory Board, EMD Serono: Advisory Board, Astra-Zeneca/MedImmune: Advisory Board, Clinical Trial, Research Funding, Lilly: Advisory Board, PPD : Advisory Board (Benitec, Immunicum), Bristol-Myers Squibb: Advisory Board, Clinical Trial, Research Funding
Cathy Eng, MD, Houston, TX - Roche,Bayer,Sirtex,Merck: Speaker's Bureau, Advaxis, Roche, Forty-Seven: Research Grants 
Kenneth K. Tanabe, MD, FACS - Helix12: Equity: Board of Directors, Cancer Experts Now: Consulting Fees: consultant on medical second opinions, Best Doctors: Consulting Fees: consultant on medical second opinions, Leidos: Consulting Fees: grant reviewer, American Cancer Society: Honoraria: Editor, UpToDate: Royalties: Editor

Program Committee and Disclosures

CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - No Disclosures
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - No Disclosures

Members

David C. Borgstrom, MD, FACS, Morgantown, WV - No Disclosures
Daniel L. Dent, MD, FACS, San Antonio, TX - No Disclosures
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Audra A. Duncan, MD, FACS, London, ON - No Disclosures
Mariam F. Eskander, MD, Boston, MA - No Disclosures
Paula Ferrada, MD, FACS, Richmond, VA - No Disclosures
Neil H. Hyman, MD, FACS, Chicago, IL - No Disclosures
Martin S. Karpeh, Jr., MD, FACS, New York, NY - No Disclosures
Dennis H. Kraus, MD, FACS, New York, NY - No Disclosures
Kenneth W. Sharp, MD, FACS, Nashville, TN - No Disclosures
David A. Spain, MD, FACS, Stanford, CA - No Disclosures

Ex-Officios

Mary T. Hawn, MD, FACS, Stanford, CA - No Disclosures
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - No Disclosures

Consultants

Barbara Lee Bass, MD, FACS, FRCS(Hon), Houston, TX - No Disclosures
Quan-Yang Duh, MD, FACS, San Francisco, CA - No Disclosures
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - No Disclosures
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - No Disclosures
Valerie W. Rusch, MD, FACS, New York, NY - No Disclosures

 

A Certificate of Completion will be awarded.

This educational activity is not eligible for CME or CE credits

Available Credit

  • 0.00 AMA PRA Category 1 Credit™
  • 0.00 Self Assessment Credit
  • 0.00 Certificate of Completion

Accreditation Period

Course opens: 
10/05/2018
Course expires: 
12/31/2019
Please login or register to take this course.